8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Mar 11, 2026·SEC
CERo Therapeutics Holdings, Inc.(CERO)Earnings, Financials & Key Ratios
CERO•NASDAQ
$0.01
Price updated Jun 27, 2026
AboutCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$17M-22.9%
- Net Income-$20M-157.6%
- EPS (Diluted)-22.58-228.7%
CERO Price & Volume
CERo Therapeutics Holdings, Inc. (CERO) stock price & volume — 10-year historical chart
Loading chart...
CERO Growth Metrics
CERo Therapeutics Holdings, Inc. (CERO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-96.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-47%
Return on Capital
10 Years-17.97%
5 Years-17.97%
3 Years-50.69%
Last Year-
CERO Recent Earnings
CERo Therapeutics Holdings, Inc. (CERO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (60%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.20+75.0%
$0.80
Rev
—
—
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.75+0.0%
$0.75
Rev
—
—
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$9.10-1097.4%
$0.76
Rev
—
—
Q3 2025
Aug 22, 2025Metric
Actual
Est
EPS
$61.71+50.3%
$124.26
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.20vs $0.80+75.0% | — |
| Q1 2026 | Feb 25, 2026 | $0.75vs $0.75+0.0% | — |
| Q4 2025 | Nov 19, 2025 | $9.10vs $0.76-1097.4% | — |
| Q3 2025 | Aug 22, 2025 | $61.71vs $124.26+50.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CERo Therapeutics Holdings, Inc. (CERO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $313.43K | -0.00 | — | — | — | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $2.13 | $519.44M | -2.45 | -100% | — | -56.45% | — | |
| $54.92 | $5.3B | -8.49 | -89.97% | -13856.54% | -30.88% | — | |
| $34.81 | $3.58B | -42.98 | 120.01% | -49.17% | -5.89% | — | |
| $16.68 | $1.87B | -4.38 | 16.92% | -597.04% | -57.27% | — |
Compare CERO vs Peers
CERo Therapeutics Holdings, Inc. (CERO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CERO SEC Filings & Documents
CERo Therapeutics Holdings, Inc. (CERO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CERO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CERO Frequently Asked Questions
CERo Therapeutics Holdings, Inc. (CERO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CERO profitable?
CERo Therapeutics Holdings, Inc. (CERO) reported a net loss of $20.7M for fiscal year 2025.
Dividend & Returns
What is CERo Therapeutics Holdings, Inc.'s free cash flow?
CERo Therapeutics Holdings, Inc. (CERO) had negative free cash flow of $14.4M in fiscal year 2025, likely due to heavy capital investments.